Literature DB >> 2573618

The beta-adrenergic agonist isoproterenol suppresses experimental allergic encephalomyelitis in Lewis rats.

E Chelmicka-Schorr1, M N Kwasniewski, B E Thomas, B G Arnason.   

Abstract

Treatment with the beta-adrenergic agonist isoproterenol suppresses clinical and histological experimental allergic encephalomyelitis in Lewis rats. The effect of isoproterenol treatment is greater when the drug is given from the time of immunization through the acute phase of the illness or from 8 to 14 days post-immunization than when given for the first 7 days after immunization.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2573618     DOI： 10.1016/0165-5728(89)90138-0

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  10 in total

Review 1.  Autonomic regulation of neuroimmunological responses: implications for multiple sclerosis.

Authors:  E M Frohman; N L Monson; A E Lovett-Racke; M K Racke
Journal:  J Clin Immunol       Date:  2001-03       Impact factor: 8.317

Review 2.  Sympathetic modulation of immunity: relevance to disease.

Authors:  Denise L Bellinger; Brooke A Millar; Sam Perez; Jeff Carter; Carlo Wood; Srinivasan ThyagaRajan; Christine Molinaro; Cheri Lubahn; Dianne Lorton
Journal:  Cell Immunol       Date:  2008-03-04       Impact factor: 4.868

Review 3.  Cardiovascular Autonomic Dysfunction: Link Between Multiple Sclerosis Osteoporosis and Neurodegeneration.

Authors:  Zohara Sternberg
Journal:  Neuromolecular Med       Date:  2018-02-10       Impact factor: 3.843

4.  Ozone Therapy in Ethidium Bromide-Induced Demyelination in Rats: Possible Protective Effect.

Authors:  Neveen A Salem; Naglaa Assaf; Manal F Ismail; Yasser A Khadrawy; Mohga Samy
Journal:  Cell Mol Neurobiol       Date:  2015-10-14       Impact factor: 5.046

Review 5.  Central nervous system-immune system interactions: psychoneuroendocrinology of stress and its immune consequences.

Authors:  P H Black
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

Review 6.  Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol).

Authors:  Karim Makhlouf; Howard L Weiner; Samia J Khoury
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

7.  Increasing CNS noradrenaline reduces EAE severity.

Authors:  Maria Vittoria Simonini; Paul E Polak; Anthony Sharp; Susan McGuire; Elena Galea; Douglas L Feinstein
Journal:  J Neuroimmune Pharmacol       Date:  2009-12-04       Impact factor: 4.147

Review 8.  Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?

Authors:  Marco Cosentino; Franca Marino
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-17       Impact factor: 4.147

9.  Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production.

Authors:  Cinzia Dello Russo; Anne I Boullerne; Vitaliy Gavrilyuk; Douglas L Feinstein
Journal:  J Neuroinflammation       Date:  2004-06-30       Impact factor: 8.322

10.  Control of lymphocyte egress from lymph nodes through β2-adrenergic receptors.

Authors:  Akiko Nakai; Yuki Hayano; Fumika Furuta; Masaki Noda; Kazuhiro Suzuki
Journal:  J Exp Med       Date:  2014-11-24       Impact factor: 14.307
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.